Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database

被引:21
作者
Kim, Jin Seok [1 ]
Liu, Yanfang [2 ]
Ha, Kyoung Hwa [3 ]
Qiu, Hong [4 ]
Rothwell, Lee Anne [5 ]
Kim, Hyeon Chang [6 ]
机构
[1] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Janssen Res & Dev, Global Epidemiol, Singapore, Singapore
[3] Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon, South Korea
[4] Janssen Res & Dev, Global Epidemiol, Titusville, NJ USA
[5] Janssen Med Affairs, Macquarie Pk, Australia
[6] Yonsei Univ, Dept Preventat Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2020年 / 52卷 / 04期
关键词
Non-Hodgkin lymphoma; Prevalence; Incidence; Korea; Second primary neoplasms; SECONDARY MALIGNANCIES; FOLLICULAR LYMPHOMA; MULTIPLE-MYELOMA; UNITED-STATES; RISK; NEOPLASMS; SUBTYPE;
D O I
10.4143/crt.2020.089
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and rates of second primary malignancies (SPM) in these patients are not known. We aimed to describe temporal changes in BNHL epidemiology and SPM incidence in Korea. Materials and Methods A retrospective cohort study used claims data from the National Health Insurance Service that provides universal healthcare coverage in Korea. Newly diagnosed patients aged at least 19 years with a confirmed diagnosis of one of six BNHL subtypes (diffuse large cell B-cell lymphoma [DLBCL], small lymphocytic and chronic lymphocytic [CLL/SLL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia [WM]) during the period 2006-2015 were enrolled and followed up until death, dis-enrolment, or study end, whichever occurred first. Patients with pre-existing primary cancers prior to the diagnosis of BNHL were excluded. Results A total of 19,500 patients with newly diagnosed BNHL were identified out of 27,866 with non-Hodgkin lymphoma (NHL). DLBCL was the most frequently diagnosed subtype (41.9%-48.4% of NHL patients annually, 2011-2015). Standardized incidence of the six subtypes studied per 100,000 population increased from 5.74 in 2011 to 6.96 in 2015, with most increases in DLBCL, FL, and MZL. The incidence (95% confidence interval) of SPM per 100 person-years was 2.74 (2.26-3.29) for CLL/SLL, 2.43 (1.57-3.58) for MCL, 2.41 (2.10-2.76) for MZL, 2.23 (2.07-2.40) for DLBCL, 1.97 (1.61-2.38) for FL, and 1.41(0.69-2.59) for WM. Conclusion BNHL has been increasingly diagnosed in Korea. High rates of SPM highlight the need for continued close monitoring to ensure early diagnosis and treatment.
引用
收藏
页码:1262 / 1272
页数:11
相关论文
共 26 条
[1]   Non-Hodgkin lymphoma [J].
Armitage, James O. ;
Gascoyne, Randy D. ;
Lunning, Matthew A. ;
Cavalli, Franco .
LANCET, 2017, 390 (10091) :298-310
[2]   Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations [J].
Bassig, Bryan A. ;
Cerhan, James R. ;
Au, Wing-Yan ;
Kim, Hee Nam ;
Sangrajrang, Suleeporn ;
Hu, Wei ;
Tse, Jovic ;
Berndt, Sonja ;
Zheng, Tongzhang ;
Zhang, Heping ;
Pornsopone, Pattarapong ;
Lee, Je-Jung ;
Kim, Hyeoung-Joon ;
Skibola, Christine F. ;
Vijai, Joseph ;
Burdette, Laurie ;
Yeager, Meredith ;
Brennan, Paul ;
Shin, Min-Ho ;
Liang, Raymond ;
Chanock, Stephen ;
Lan, Qing ;
Rothman, Nathaniel .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) :442-448
[3]   Insights into the molecular pathogenesis of follicular lymphoma, arising from analysis of geographic variation [J].
Biagi, JJ ;
Seymour, JF .
BLOOD, 2002, 99 (12) :4265-4275
[4]   Secondary malignancies in patients with multiple myeloma, Waldenstrom macroglobulinemia and monoclonal gammopathy of undetermined significance [J].
Castillo, Jorge J. ;
Gertz, Morie A. .
LEUKEMIA & LYMPHOMA, 2017, 58 (04) :773-780
[5]   Familial predisposition and genetic risk factors for lymphoma [J].
Cerhan, James R. ;
Slager, Susan L. .
BLOOD, 2015, 126 (20) :2265-2273
[6]   Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 Revision of the World Health Organization Classification [J].
Chuang, Shih-Sung ;
Chen, Shang-Wen ;
Chang, Sheng-Tsung ;
Kuo, Yu-Ting .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (08) :620-625
[7]   Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years [J].
Engelhardt, Monika ;
Ihorst, Gabriele ;
Landgren, Ola ;
Pantic, Milena ;
Reinhardt, Heike ;
Waldschmidt, Johannes ;
May, Annette M. ;
Schumacher, Martin ;
Kleber, Martina ;
Waesch, Ralph .
HAEMATOLOGICA, 2015, 100 (10) :1340-1349
[8]   A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas [J].
Feugier, Pierre .
FUTURE ONCOLOGY, 2015, 11 (09) :1327-1342
[9]   Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study [J].
Giri, Smith ;
Bhatt, Vijaya Raj ;
Verma, Vivek ;
Pathak, Ranjan ;
Bociek, R. Gregory ;
Vose, Julie M. ;
Armitage, James O. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (09) :569-574
[10]   Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 [J].
Jung, Kyu-Won ;
Won, Young-Joo ;
Kong, Hyun-Joo ;
Lee, Eun Sook .
CANCER RESEARCH AND TREATMENT, 2018, 50 (02) :303-316